AtriCure (NASDAQ:ATRC) shares traded up 8.5% on Friday after Stifel Nicolaus raised their price target on the stock from $22.00 to $23.00. Stifel Nicolaus currently has a buy rating on the stock. AtriCure traded as high as $23.69 and last traded at $22.38. 506,610 shares traded hands during mid-day trading, an increase of 134% from the average session volume of 216,195 shares. The stock had previously closed at $20.62.

Several other research analysts also recently weighed in on ATRC. Needham & Company LLC lifted their target price on shares of AtriCure from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday. BidaskClub raised shares of AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, March 17th. TheStreet raised shares of AtriCure from a “d+” rating to a “c-” rating in a research report on Friday, March 16th. Canaccord Genuity lifted their target price on shares of AtriCure from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, ValuEngine raised shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AtriCure has an average rating of “Buy” and an average price target of $25.00.

In related news, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Justin J. Noznesky sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $17.03, for a total transaction of $68,120.00. The disclosure for this sale can be found here. Insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in AtriCure by 22.1% during the fourth quarter. BlackRock Inc. now owns 2,731,558 shares of the medical device company’s stock valued at $49,823,000 after purchasing an additional 494,306 shares in the last quarter. Peregrine Capital Management LLC grew its position in AtriCure by 22.7% during the fourth quarter. Peregrine Capital Management LLC now owns 1,134,406 shares of the medical device company’s stock valued at $20,692,000 after purchasing an additional 209,666 shares in the last quarter. Victory Capital Management Inc. grew its position in AtriCure by 3.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,068,895 shares of the medical device company’s stock valued at $19,497,000 after purchasing an additional 40,550 shares in the last quarter. Citadel Advisors LLC grew its position in AtriCure by 13.2% during the fourth quarter. Citadel Advisors LLC now owns 378,639 shares of the medical device company’s stock valued at $6,906,000 after purchasing an additional 44,074 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in AtriCure by 3.8% in the fourth quarter. Royce & Associates LP now owns 290,799 shares of the medical device company’s stock valued at $5,304,000 after acquiring an additional 10,599 shares during the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

The company has a current ratio of 2.58, a quick ratio of 1.87 and a debt-to-equity ratio of 0.23. The company has a market cap of $716.97, a PE ratio of -25.29 and a beta of 0.26.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, April 26th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). The business had revenue of $46.99 million during the quarter, compared to analyst estimates of $45.43 million. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. AtriCure’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) earnings per share. equities research analysts expect that AtriCure will post -0.83 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.